CytomX Therapeutics, Inc.
CTMX
$3.79
-$0.09-2.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 663.00K | 5.96M | 18.66M | 50.92M | 38.09M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 663.00K | 5.96M | 18.66M | 50.92M | 38.09M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 663.00K | 5.96M | 18.66M | 50.92M | 38.09M |
| SG&A Expenses | 6.26M | 6.43M | 6.62M | 9.43M | 5.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.80M | 21.73M | 19.94M | 28.30M | 20.41M |
| Operating Income | -25.13M | -15.77M | -1.29M | 22.62M | 17.68M |
| Income Before Tax | -26.46M | -14.17M | -91.00K | 23.59M | 18.94M |
| Income Tax Expenses | 54.00K | 58.00K | 63.00K | 62.00K | 62.00K |
| Earnings from Continuing Operations | -26.51M | -14.23M | -154.00K | 23.53M | 18.88M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.51M | -14.23M | -154.00K | 23.53M | 18.88M |
| EBIT | -25.13M | -15.77M | -1.29M | 22.62M | 17.68M |
| EBITDA | -24.62M | -15.63M | -939.00K | 23.01M | 18.09M |
| EPS Basic | -0.17 | -0.09 | 0.00 | 0.27 | 0.22 |
| Normalized Basic EPS | -0.09 | -0.05 | 0.00 | 0.17 | 0.14 |
| EPS Diluted | -0.18 | -0.09 | 0.00 | 0.27 | 0.22 |
| Normalized Diluted EPS | -0.09 | -0.05 | 0.00 | 0.17 | 0.14 |
| Average Basic Shares Outstanding | 169.69M | 165.00M | 129.08M | 87.12M | 85.74M |
| Average Diluted Shares Outstanding | 169.69M | 165.00M | 129.08M | 87.15M | 85.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |